Alteon Inc.

29 articles about Alteon Inc.

• Alzheimer's Biotech Cognition Therapeutics Taps Chimerix-Alteon Vet as New CEO

  10/28/2016

• Alteon Reverse Stock Split and Name Change to Become Effective on July 25th

  7/24/2007

• Alteon Stockholders Approve Amendments to Certificate of Incorporation at Annual Meeting

  7/23/2007

• Alteon to Hold Annual Meeting of Stockholders

  7/18/2007

• Alteon Appoints Jacob Victor, Ph.D. to Lead Development of Haptoglobin Diagnostic Test

  7/16/2007

• Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

  6/28/2007

• Alteon to Present at Rodman & Renshaw's Annual Health Care Conference

  5/10/2007

• Alteon Issues Update Regarding Auditors' Going Concern Report

  4/20/2007

• Alteon Announces Entry Into Definitive Documents for the Sale of $25 Million in a Private Financing of Its Series B Preferred Stock

  4/9/2007

• Alteon and OXIS International, Inc. Expand Licensing Deal to Include Exclusive Rights of Organoselenium Compounds for All Indications

  4/9/2007

• Alteon Expands Licensing Agreement With Biorap Technologies for Diagnostic Assays That Identify High Risk Cardiovascular Patients

  4/6/2007

• Alteon's Investigational Drug Alagebrium Demonstrates Ability To Improve Functional Membrane Transport In A Rat Model Of Chronic Peritoneal Dialysis, Indicating A Potential Role In Kidney Disease

  2/20/2007

• Alteon's ALT-2074 Demonstrates Ability To Reduce Infarct Size By 80 Percent In Mice With Haptoglobin 2-2 Genotype

  11/13/2006

• Alteon Notified By AMEX Of Continued Listing Standards Non-Compliance; Company Expects Its Common Stock To Remain Listed While It Engages In AMEX Compliance Process

  10/16/2006

• Alteon To Present At The Biotechnology Industry Organization (BIO) InvestorForum 2006

  10/11/2006

• Alteon's Alagebrium To Be Evaluated In National Institutes of Health (NIH)-Funded Phase 2 Clinical Study Focused On Cardiovascular Aging

  9/28/2006

• New Alteon Management Focuses Its Development Of Alagebrium On Heart Failure With Preserved Ejection Fraction

  9/12/2006

• Alteon And HaptoGuard, Inc. Shareholders Approve Merger

  7/20/2006

• Alteon Research Collaborator Receives Funding From Juvenile Diabetes Research Foundation For Diabetic Complications Clinical Study Investigating Alagebrium And Renal Function

  7/10/2006

• Alteon Announces Financial Results For The First Quarter Ended March 31, 2006

  5/16/2006